

5-27-2022

Toward Zero Prescribed Opioids for Outpatient General Surgery Procedures: A Prospective Cohort Trial

Ryan Lamm

Thomas Jefferson University

Steven Woodward

Thomas Jefferson University

Brandon A Creisher

Thomas Jefferson University

David Nauheim

Thomas Jefferson University

Lauren Schlegel

Thomas Jefferson University

Follow this and additional works at: <https://jdc.jefferson.edu/surgeryfp>



Part of the [Surgery Commons](#)

See next page for additional authors

[Let us know how access to this document benefits you](#)

Recommended Citation

Lamm, Ryan; Woodward, Steven; Creisher, Brandon A; Nauheim, David; Schlegel, Lauren; Tatarian, Talar; Tholey, Renee; Foley, Courtney; and Palazzo, Francesco, "Toward Zero Prescribed Opioids for Outpatient General Surgery Procedures: A Prospective Cohort Trial" (2022). *Department of Surgery Faculty Papers*. Paper 218.

<https://jdc.jefferson.edu/surgeryfp/218>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Surgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Ryan Lamm, Steven Woodward, Brandon A Creisher, David Nauheim, Lauren Schlegel, Talar Tatarian, Renee Tholey, Courtney Foley, and Francesco Palazzo

Toward zero prescribed opioids for outpatient general surgery procedures: a prospective cohort trial

Short Title: Zero Opioid General Surgery

Ryan Lamm, MD; Steven Woodward, MD; Brandon A. Creisher, BS; David Nauheim, BS; Lauren Schlegel, BS; Talar Tatarian, MD; Renee Tholey MD; Courtney Foley, RN; Francesco Palazzo, MD

From the: Department of Surgery, Sidney Kimmel Medical College at Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA, USA 19107

Corresponding author: Ryan Lamm, MD; Department of Surgery, Thomas Jefferson University Hospital, 111 South 11th Street, Philadelphia, PA USA 19107 (email: ryan.lamm@jefferson.edu; Phone Number: 215-955-8666)

Author contributions: RL conducted contributed to study design, data collection, statistical analysis, manuscript writing, and manuscript editing. SW contributed to study design and manuscript editing. BC, DN, and LS contributed to data collection and manuscript editing. TT and RT contributed to study design and manuscript editing. CF contributed to data collection, study design, and manuscript editing. FP contributed to study design, manuscript writing, and manuscript editing and was the principal investigator on the study.

1 **ABSTRACT**

2 **Background:** Achieving satisfactory post-operative pain control for common elective general
3 surgical procedures, while minimizing opioid utilization, remains challenging. Utilizing pre-
4 operative educational strategies, as well as multimodal analgesia, we sought to reduce the post-
5 operative opioid use in elective general surgery cases.

6 **Methods:** Between November 2019 and July 2021, patients undergoing elective inguinal hernia
7 repair (IHR) or cholecystectomy were enrolled in the study. Patients were divided into three
8 cohorts: Control, opioid sparing (OS), or zero-opioid (ZO). Control patients did not have any
9 intervention; OS patients had an opioid reduction intervention protocol applied (patient
10 education and perioperative multimodal analgesia) and were provided an opioid prescription at
11 discharge; the ZO had the same protocol, however patients were not provided opioid
12 prescriptions at discharge. Two weeks after discharge patients were interviewed to record
13 opioid consumption, pain scores, and level of satisfaction since discharge.

14 **Results:** 129 patients were recruited for the study. 88 patients underwent inguinal hernia repair
15 and 41 patients underwent cholecystectomy. Median post-operative morphine equivalents
16 consumed in the Control cohort (n=58); 46 (37.5-75) were significantly reduced when the OS
17 protocol was enacted (n=42); 15 (11-22.5) and further reduced to zero for every patient in the
18 ZO cohort (n=29) ($p=0.0001$). There were no differences in patient-reported average pain
19 scores after discharge ($p=0.08$) or satisfaction levels with experience ($p=0.8302$).

20 **Conclusions:** Our study demonstrates that patient education and preoperative interventions
21 can result in zero opioids prescribed after common general surgery procedures with equivalent
22 patient satisfaction and pain scores.

23 **Keywords:** Postoperative Pain Control; Opioid Reduction; General Surgery

24 INTRODUCTION

25 In 2021, the Center for Disease Control (CDC) reported an estimated 100,306 overdose
26 deaths from opioids in the United States (US).¹ Since 2015, opioid overdose has been the
27 leading cause of injury-related deaths in the US, with 6% of the US population reportedly
28 abusing opioids compared to <1% in most other countries.^{2,3} Medical prescribers represent the
29 only legal source contributing to available opioids, with a substantial portion coming from
30 procedure-based specialists. One Veterans Affairs (VA) study measured the number of
31 outpatient opioid prescriptions at 10,256,706 over three years from proceduralists.⁴ The
32 percentage of these pills that go unused ranges from 54-86%.⁵⁻⁷ For general surgeons
33 specifically, the number has been reported at 71% of prescribed pills.⁸

34 Each year in the United states, approximately 800,000 inguinal hernia repairs and
35 300,000 cholecystectomies are performed.⁹ Previous reports noted that, on average, physicians
36 prescribed around 33 opioid pills for inguinal hernia repairs and 35 for cholecystectomies.⁸
37 These patterns would result in approximately 26.4 million opioids being prescribed for inguinal
38 hernia repairs and 10.5 million for cholecystectomy; factoring in the estimated 71%, there could
39 be up to 18.8 million of these opioid pills possibly available to enter the community.⁸

40 In response to the opioid crisis, professional medical societies, organizations, and state
41 medical boards have been working diligently to contain the number of opioids prescribed and
42 educate physicians on appropriate prescribing patterns (*i.e.*, American College of Surgeons
43 (ACS) Safe and Effective Pain Control After Surgery).¹⁰ Despite these efforts, there is an
44 opportunity for physician and patient-level interventions targeting both increased education and
45 non-opioid pain control in common outpatient general surgery procedures.

46 Our study sought to evaluate the impact of an opioid reduction protocol (which combined
47 multiple strategies: patient-education, non-opioid perioperative pain management, and safe
48 opioid prescribing practices) on postoperative opioid utilization. We hypothesized that a

49 standardized protocol for common outpatient general surgery procedures, could decrease
50 opioids utilization at our institution without compromising pain control or patient satisfaction.

51

52 **METHODS**

53 **Study design:** This was a prospective cohort study and was approved by the Institutional
54 Review Board (IRB) of Thomas Jefferson University on October 2019 prior to patient enrollment
55 (Control #19D.688) and registered on clinicaltrials.gov (NCT05327777). This study was exempt
56 from requiring informed consent.

57 **Inclusion and Exclusion Criteria.** The study took place between November 2019 and July
58 2021 at a single academic medical center. Inclusion criteria included: opioid naïve patients, age
59 > 18, being scheduled for an outpatient, elective inguinal hernia repair or cholecystectomy with
60 one of three general surgeons. Exclusion criteria included: urgent/emergent status, and/or
61 previous cholecystostomy tube placement.

62 **Opioid reduction Intervention Protocol:** The protocol (**Table 1**) included: a) an educational
63 component provided at the outpatient visit with the surgeon with instructions tailored to the
64 specific procedure, as well as the American College of Surgeon's (ACS) Safe and Effective Pain
65 Control After Surgery patient tool¹⁰ (**Figure 1**); b) preoperative multimodal analgesia provided 1
66 hour prior to operation (800 milligrams (mg) of ibuprofen, 1,000 mg of acetaminophen, and 75
67 mg of pregabalin for patients <70 years old); c) goal-directed fluid management, limited
68 intraoperative opioid administration at the discretion of the anesthesiologist, and local anesthetic
69 administered at incision sites; d) postoperative elements of the protocol included limited PACU
70 administration of opioids based on pain scores (opioids only allowed for pain visual analog
71 score (VAS) > 6), discharge counseling regarding limited opioid use at home, and instructions to
72 alternate between acetaminophen and ibuprofen every 3 hours at home for pain.

73 Prior to the launch of the study, the senior author held two consecutive educational
74 sessions on the protocol and its implementation with the perioperative nursing, anesthesia, and
75 surgical staff.

76 ***Phases of Study and Chronology of Interventions.*** The study was designed to have an
77 assessment phase (referred to as the “Control” cohort) and two intervention phases (**Figure 2**).

78 In the assessment phase of the study (November 2019 - February 2020), in order to
79 establish a reference control cohort, patients were monitored for their opioid utilization per
80 routine, established practice, prior to any intervention. In the intervention phases, data were
81 collected after the opioid reduction intervention protocol was initiated (**Table 1**).

82 In the intervention phases, two chronologically consecutive intervention cohorts were
83 created. In the first one (“Opioid Sparing” (OS); March 2020 - October 2020), patients were
84 discharged with instructions to alternate between acetaminophen and ibuprofen and to use the
85 opioids only for breakthrough pain (prescription for 10 pills of 5 milligram oxycodone or 50
86 milligram tramadol every 4-6 hours was provided at discharge); in the second cohort (“Zero
87 Opioid” (ZO); November 2020 - July 2021), patients were discharged without a prescription for
88 opioids, but rather instructed to contact the provider should pain control not be adequate with
89 acetaminophen and ibuprofen alone. Importantly, it is worth noting that at our institution elective
90 cases were cancelled due to the COVID-19 pandemic during the intervention phases which
91 impacted the sample size, as well as decision of when to move on to the ZO stage of the
92 protocol.

93 ***Data Collection.*** Demographic, clinical, and perioperative variables were collected by
94 retrospective review of the electronic medical record and included age, sex, race/ethnicity, BMI,
95 American Society of Anesthesiologists (ASA) class, smoking status, history of substance abuse,
96 procedure, technique (open, laparoscopic, or robotic), whether the minimally invasive inguinal

97 repair was trans-abdominal pre-peritoneal (TAPP) or totally extra-peritoneal (TEP), length of
98 procedure, estimated blood loss, total intravenous fluid given during the procedure, total local
99 anesthetic given during the procedure, total intraoperative morphine milliequivalents
100 administered, length of stay after procedure, and patient-reported pain scores at 1 hour after the
101 procedure and at discharge.

102 **Outcomes.** Outcome variables were obtained by the electronic medical record and/or by
103 utilization of a brief telephone survey (intended for internal use only) which was administered by
104 members of the study team who contacted the patients 14 days after discharge (**Figure S1**).

105 Outcomes of interest included: total morphine milligram equivalents (MMEs) in the post-
106 anesthesia care unit (PACU), patient-reported total MMEs after discharge, and patient-reported
107 pain scores and satisfaction scores after discharge. Satisfaction scores were on a scale of 1 to
108 10 with 1 being extremely dissatisfied and 10 being extremely satisfied. Additionally, number of
109 calls to the surgeon's office with a complaint of pain and number of pain medication refills
110 prescribed were recorded for 30 days following the procedure. For MME calculations, patients
111 were asked how many pills of each pain medication they had taken after discharge and based
112 on their responses these were converted and recorded by the research team.

113 **Statistical Analysis.** Chi-square test was used to compare categorical variables. For
114 continuous variables, Shapiro-Wilk test was performed to determine if data were normally
115 distributed. For normally distributed data, analysis of variance (ANOVA) test was performed,
116 and results were reported as means with standard deviations. For variables that were not
117 normally distributed, Kruskal-Wallis's test was performed, and results were reported as medians
118 with interquartile ranges (IQR). For all comparisons two-sided statistical significance was set a
119 priori at $p < 0.05$. All statistical analyses were performed using Stata/MP 17.1 (Statacorp, College
120 Station, TX).

121

122 **RESULTS**

123 **Demographic and Clinical Characteristics.** One hundred and forty-eight patients met
124 inclusion criteria, however only 129 had complete follow-up and were enrolled in the study: 58
125 patients in the Control cohort, 42 in the Opioid Sparing cohort (OS), and 29 in the Zero-Opioid
126 cohort (ZO). Demographic and clinical characteristics were statistically equivalent between
127 cohorts, except for significantly fewer female patients being present in the ZO cohort (6.9%)
128 compared to the Control (32.8%) and OS (23.8%) cohorts ($p=0.029$) and (**Table 2**).

129 **Perioperative Characteristics.** Between cohorts, more inguinal hernias were done in the ZO
130 and OS cohorts than the Control (ZO: 25/29 (86.2%) v OS: 31/42 (73.8%) v Control: 32/58
131 (55.2%), $p=0.009$). More open procedures were performed in the ZO and OS cohorts as well
132 (ZO: 37.9% v OS: 35.7% v Control: 18.2%, $p=0.017$) compared to minimally invasive or robotic.
133 Length of stay after the procedure was significantly longer in the ZO and OS groups (ZO: 5.1
134 hours v OS: 4.7 hours v Control: 2.7 hours, $p=0.0001$) (**Table 3**). Estimated blood loss, total
135 intravenous fluid given, and total intraoperative MME were statistically, but not clinically,
136 different. The rest of the perioperative characteristics studied were statistically equivalent.

137 **Postoperative Outcomes.** Total MMEs after discharge were significantly reduced from Control
138 (46 (37.5-75)) to (15 (11-22.5) in the OS cohort and further reduced to zero in the ZO cohort
139 ($p=0.0001$). No significant differences were seen in the patient-reported pain ($p=0.08$) or
140 satisfaction scores ($p=0.8302$) after discharge. The number of calls to the surgeon's office with
141 complaints of pain as well as number of pain medication refills prescribed within 30 days of
142 operation were both zero in the ZO cohort (**Table 4**). Additionally, no patients in any cohort
143 presented to the emergency room after their operation with a complaint of pain or request for
144 pain medications in our study.

145

146 **DISCUSSION**

147 In the United States 1.1 million elective inguinal hernia repairs and cholecystectomies
148 are performed each year, with 26.4 million opioid pills being prescribed to treat postoperative
149 pain, with more than two-thirds of those pills at risk of being unused and available to circulate in
150 the community.^{8,9} We believe that despite previous successful interventions implemented,
151 elective general surgery procedures represent a significant opportunity to critically reduce the
152 total amount of opioids prescribed by surgeons.

153 Our study utilized a perioperative opioid reduction intervention protocol to first
154 significantly reduce the number of opioids used by patients after discharge from common
155 elective general surgery and then, subsequently, drive that number down to zero by not
156 providing an opioid prescription at discharge. During this study period, there was no significant
157 difference in pain or satisfaction scores, suggesting patient experience and care were not
158 compromised. Finally, we saw a reduction in office calls and pain medication refills prescribed to
159 zero. We attributed this change to the increased efforts towards patient education both pre- and
160 post-operatively. Our results provide a framework to reduce opioid overuse, by directly
161 intervening on patients undergoing common surgical interventions and increasing awareness on
162 postoperative pain management and proper disposition of unused pills.

163 Strategies to successfully reduce opioid use across various procedural fields including
164 colorectal surgery¹¹, neurosurgery¹², and general surgery¹³ have been proven in previous
165 studies. For example, Hartford *et al* were able to decrease the total morphine milligram
166 equivalents (MMEs) in postoperative cholecystectomy and open hernia repair patients from 100
167 to 50 utilizing multi-modal, non-narcotic, intra-and postoperative analgesia bundles and showed
168 non-inferior pain scores after application between control and intervention patient cohorts.¹⁴
169 Others, like Angelo *et al*, using solely patient-education based infographics, successfully

170 reduced the number of opioid pills prescribed in half from 30 to 15.¹⁵ Our study combined these
171 approaches to create a multifaceted protocol to reduce opioid utilization.

172 Many state, society, and institution-level interventions have been implemented to reduce
173 the opioid prescribing rate. On the state level, legislative restrictions have been implemented on
174 the number of opioids allowed to be prescribed for certain procedures.¹⁶ Additionally, as
175 mentioned earlier, the ACS has published multiple educational materials for providers on
176 appropriate prescribing practices and for patients on appropriate indications for opioid
177 consumption for common surgical procedures.¹⁰ Finally, at the institution level, specific
178 education materials have been published to target at-risk patient populations.¹⁷ In addition,
179 pathways which work towards reducing perioperative opioid use, namely the enhanced recovery
180 after surgery (ERAS) protocols, have been implemented for select procedures.¹⁸ All of these
181 interventions have had success on lowering the amount of opioid consumption and prescribing
182 however, few specifically target elective outpatient procedures.

183 On top of these efforts, recent calls to arms have highlighted the need to eliminate
184 prescriptions completely. This is obviously not realistic for all procedures, but is a strategy
185 advocated for and utilized by some routine minimally invasive teams. One example is the
186 robotics urology team at the University of Pittsburgh that, anecdotally, describes how they
187 stopped prescribing opioids for their robotic prostatectomy and nephrectomy patients
188 postoperatively, without an observed increase in emergency room visits for pain or outpatient
189 phone calls.¹⁹ These authors advocate “anchoring to zero exposure” by simply not prescribing
190 patients opioids after their surgery and educating them on the use of non-narcotic pain control at
191 home. While our ZO cohort was 100% successful in this study, that level of success will likely
192 vary from institution to institution and procedure to procedure, considering the majority of cases
193 in our study was performed by a small group of surgeons with one contributing a majority of the
194 cases.

195 We believe a key to our success in driving opioid utilization toward zero in our study,
196 was the requirement to call the office should the patient need an opioid prescription, instead of
197 providing one on discharge. In our study, patients went from taking 46 MMEs after discharge in
198 the control cohort to 15 in the OS and 0 in the ZO group. This equates to around six 5mg
199 oxycodone pills taken in the Control group and one to two pills in the OS group. Within the OS
200 group, when asked why they had taken the 1-2 pills over the two-week period, many patients
201 reported using the opioids as first line pain control, to aid in sleep, and/or simply because they
202 thought they were supposed to since their surgeon had prescribed them. Once the prescription
203 was removed from the routine discharge materials, patients easily adjusted to the
204 recommendations, few calls occurred, and no additional opioids were requested. These findings
205 were not combined with any significant increase in reported pain from our cohort. We believe
206 that in correctly selected procedures, opioid prescriptions should no longer be routinely
207 provided. A critically important component of the study's protocol was early education and
208 engagement of the entire perioperative nursing, anesthesia, and surgery staff with the elements
209 of the intervention.

210 An important point to consider in implementing opioid reduction protocols is cost. As we
211 reported, patients in both intervention arms spent longer in the hospital and received additional
212 medications preoperatively which, while challenging to assign a true expense to, likely drove the
213 hospital costs higher. Some previous studies have shown that these types of pathways are cost-
214 effective when considering reduced re-admissions and post-operative complications²⁰⁻²²,
215 however some showed no difference.^{23, 24} No studies we identified showed an overall increase
216 in cost after implementation. In our experience, while costs may be higher in the index
217 admission, these types of pathways are ultimately cost-effective in their ability to reduce
218 subsequent healthcare resource utilization and physician-contribution to the opioid epidemic.

219 That being said, formal cost-effectiveness analysis would need to be performed to truly capture
220 the full economic impact of implementing these types of protocols.

221 An additional, and certainly significant, benefit of these efforts aimed at reducing the
222 number of available opioids was education in appropriately discarding unused pills. We believe
223 this information should be included in all pre- and post-operative patient education with the
224 same emphasis we place on keeping wounds clean and notifying a physician should any
225 complications arise. In our study, instructions on how to discard opioids properly were included
226 in our patient education handout (**Figure 1**). Porter *et al* utilized strong patient education and a
227 “convenient drop-box” in their hospital’s pharmacy, with directions to its location provided to the
228 patient, to achieve a rate of 83% FDA-compliant disposal of excess pills in their cohort.²⁵ We
229 believe FDA-compliant drop-boxes should be located in all hospital pharmacies. We also
230 suggest the implementation of programs where patients can appropriately dispose their unused
231 opioids at their postoperative appointments to increase convenience, but more importantly
232 compliance.

233 *Limitations*

234 There were a few limitations in our study worth noting. For one, this study was
235 performed on only general surgery, opioid naïve, elective patients and, thus, it is likely not
236 generalizable to patients outside of this inclusion criteria. However, other studies have shown
237 success with similar programs in higher acuity and chronic pain patient populations.²⁶ Moreover,
238 some clinically significant demographic and perioperative characteristics were statistically
239 different between our cohorts. For one, there were significantly less females and more open
240 procedures in the zero-opioid (ZO) cohort and opioid sparing (OS) cohort. However, since men
241 have been shown to abuse opioids more frequently, and minimally invasive procedures have
242 been shown to decrease postoperative pain and subsequent opioid use, we believe these two
243 statistical differences actually strengthen the hypothesis that our intervention protocol was

244 successful since these intervention cohorts also had significantly lower opioid use.^{27, 28}
245 Additionally, we performed a sub-analysis of only the inguinal hernia repairs in our study which
246 showed the same direction of trends and significance for all demographic, clinical, and
247 postoperative variables included in our larger study except that the female to male distributions
248 were statistically equivalent. That being said, a larger study which can control for all covariates
249 should be done. We also reported a significantly longer length of stay in the ZO and OS cohorts.
250 The difference was only 2 hours which is either a product of small cohort size and chance, or a
251 real effect which, when weighed against reduction of opioids, is worth it in our opinion. We
252 utilized a survey administered via telephone or at postoperative visit which required patients to
253 recall how many pain pills had been taken after discharge which is subject to recall bias and
254 may skew the results. Also, all the procedures included in our study were performed by three
255 surgeons, with a majority of them being performed by a single surgeon, creating the potential for
256 a selection bias. Similarly, in regards to cohort size, despite our ZO intervention phase spanning
257 the longest amount of time (9 months), it contained the least number of patients (n=29). This
258 was secondary to elective cases being cancelled to the COVID-19 pandemic for a majority of
259 that time period. Despite this, we believe the cohort was adequate in size to display the
260 intended outcome effects.

261 **CONCLUSIONS**

262 With recent emphasis on opioid reduction strategies to combat the opioid dependence
263 and abuse epidemic in the US, our study demonstrated that patient education and perioperative
264 interventions can significantly reduce opioid use in the outpatient elective general surgery
265 patient. Additionally, by requiring the patient to call in to the office to obtain an opioid
266 prescription rather than providing it at discharge, we were able to drive our opioid use rate down
267 to zero while maintaining pain control and satisfaction scores. We hope our protocol can serve
268 as a model for opioid reduction in other outpatient elective surgeries and spur discussion on

269 strategies to mitigate opioid use in more urgent/emergent or extensive procedures in an effort to
270 reduce the contribution of provider-prescribed opiates to the current epidemic.

271 **ACKNOWLEDGEMENTS**

272 The authors would like to acknowledge the Department of Surgery at Thomas Jefferson
273 University for their support in this project.

274 **DISCLOSURE:**

275 The authors report no proprietary or commercial interest in any product mentioned or concept
276 discussed in this article.

277 **FUNDING:**

278 This research did not receive any specific grant from funding agencies in the public,
279 commercial, or not-for-profit sectors.

280 REFERENCES

- 281 1. Prevention, C.f.D.C.C.a. *Provisional counts of drug overdose deaths*. 2021.
- 282 2. Theisen, K., et al., *The United States opioid epidemic: a review of the surgeon's contribution*
283 *to it and health policy initiatives*. *BJU international*, 2018. **122**(5): p. 754-759.
- 284 3. Merz, F., *United Nations Office on Drugs and Crime: World Drug Report 2017*. 2017. SIRIUS-
285 *Zeitschrift für Strategische Analysen*, 2018. **2**(1): p. 85-86.
- 286 4. Evans, C.T., et al., *Outpatient Prescribing of Antibiotics and Opioids by Veterans Health*
287 *Administration Providers, 2015–2017*. *American journal of preventive medicine*, 2021.
288 **61**(5): p. e235-e244.
- 289 5. Maughan, B.C., et al., *Unused opioid analgesics and drug disposal following outpatient dental*
290 *surgery: a randomized controlled trial*. *Drug and alcohol dependence*, 2016. **168**: p. 328-
291 334.
- 292 6. Harris, K., et al., *Opioid pain medication use after dermatologic surgery: a prospective*
293 *observational study of 212 dermatologic surgery patients*. *JAMA dermatology*, 2013.
294 **149**(3): p. 317-321.
- 295 7. Bartels, K., et al., *Opioid use and storage patterns by patients after hospital discharge*
296 *following surgery*. *PLoS one*, 2016. **11**(1): p. e0147972.
- 297 8. Hill, M.V., et al., *Wide variation and excessive dosage of opioid prescriptions for common*
298 *general surgical procedures*. *Annals of surgery*, 2017. **265**(4): p. 709-714.
- 299 9. Blythe, J., et al., *Acute cholecystitis - a cohort study in a real-world clinical setting (REWO*
300 *study, NCT02796443)*. *Pragmat Obs Res*, 2018. **9**: p. 69-75.
- 301 10. Surgeons, A.C.o., *Safe and Effective Pain Control After Surgery*. *Surgical Patient Education*
302 *Program*, 2021.
- 303 11. Ivatury, S.J., et al., *Prospective Evaluation of a Standardized Opioid Reduction Protocol*
304 *after Anorectal Surgery*. *Journal of Surgical Research*, 2020. **256**: p. 564-569.
- 305 12. Eley, N., et al., *Implementation of an opioid reduction protocol for simple outpatient*
306 *neurosurgical procedures: a single-center experience*. *Spine*, 2020. **45**(6): p. 397-404.
- 307 13. Pruitt, L.C., et al., *Implementation of a quality improvement initiative to decrease opioid*
308 *prescribing in general surgery*. *Journal of Surgical Research*, 2020. **247**: p. 514-523.
- 309 14. Hartford, L.B., et al., *Standardization of outpatient procedure (STOP) narcotics: a*
310 *prospective non-inferiority study to reduce opioid use in outpatient general surgical*
311 *procedures*. *Journal of the American College of Surgeons*, 2019. **228**(1): p. 81-88. e1.
- 312 15. Angelo, J.L., et al., *Reduction in prescribed opioids after general surgery procedures at a*
313 *public hospital*. *The American Surgeon*, 2019. **85**(10): p. 1198-1203.
- 314 16. Randall, D.J., et al., *National and State Level Opioid-Restricting Legislation in Total Joint*
315 *Arthroplasty: A Systematic Review*. *The Journal of Arthroplasty*, 2022. **37**(1): p. 176-185.
- 316 17. Hill, M.V., et al., *An educational intervention decreases opioid prescribing after general*
317 *surgical operations*. *Annals of surgery*, 2018. **267**(3): p. 468-472.
- 318 18. Melnyk, M., et al., *Enhanced recovery after surgery (ERAS) protocols: Time to change*
319 *practice?* *Can Urol Assoc J*, 2011. **5**(5): p. 342-8.
- 320 19. Davies, B. and C.M. Brummett, *Anchoring to Zero Exposure: Opioid-free Minimally Invasive*
321 *Surgery*. *Annals of Surgery*, 2020. **271**(1): p. 37-38.
- 322 20. Ljungqvist, O., M. Scott, and K.C. Fearon, *Enhanced recovery after surgery: a review*. *JAMA*
323 *surgery*, 2017. **152**(3): p. 292-298.
- 324 21. Stowers, M.D., D.P. Lemanu, and A.G. Hill, *Health economics in enhanced recovery after*
325 *surgery programs*. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*,
326 2015. **62**(2): p. 219-230.
- 327 22. Stone, A.B., et al., *Implementation costs of an enhanced recovery after surgery program in*
328 *the United States: a financial model and sensitivity analysis based on experiences at a*

- 329 *quaternary academic medical center*. Journal of the American College of Surgeons,
330 2016. **222**(3): p. 219-225.
- 331 23. Lemanu, D., et al., *A systematic review to assess cost effectiveness of enhanced recovery*
332 *after surgery programmes in colorectal surgery*. Colorectal Disease, 2014. **16**(5): p. 338-
333 346.
- 334 24. Thanh, N.X., et al., *An economic evaluation of the Enhanced Recovery After Surgery*
335 *(ERAS) multisite implementation program for colorectal surgery in Alberta*. Canadian
336 Journal of Surgery, 2016. **59**(6): p. 415.
- 337 25. Porter, E.D., et al., *Guidelines for Patient-Centered Opioid Prescribing and Optimal FDA-*
338 *Compliant Disposal of Excess Pills after Inpatient Operation: Prospective Clinical Trial*.
339 Journal of the American College of Surgeons, 2021. **232**(6): p. 823-835. e2.
- 340 26. Magrum, B., et al., *Combating the opioid epidemic in acute general surgery: Reframing*
341 *inpatient acute pain management*. Journal of Surgical Research, 2020. **251**: p. 6-15.
- 342 27. Serdarevic, M., C.W. Striley, and L.B. Cottler, *Sex differences in prescription opioid use*.
343 Curr Opin Psychiatry, 2017. **30**(4): p. 238-246.
- 344 28. Hemmerling, T.M., *Pain management in abdominal surgery*. Langenbecks Arch Surg, 2018.
345 **403**(7): p. 791-803.

346 **TABLES:**347 **Table 1.** Opioid Reduction Intervention Protocol

Opioid Reduction Intervention Protocol	
Preoperative/Intraoperative Interventions	Postoperative Intervention
1) Preoperative opioid reduction education given to patients in surgeon's office (Figure 1)	1) Limited opioid administration in PACU (only for pain visual analog scores > 6)
2) Preoperative multimodal analgesia 1 hour before operation: <ul style="list-style-type: none"> • Ibuprofen 800 milligrams x 1 • Acetaminophen 1,000 milligrams x 1 • Pregabalin 75 milligrams x 1 (except for patients >70y old) 	2) Discharge counseling emphasizing importance of limited opioid use outpatient
3) Intraoperative goal-directed fluid management	3) Instructed to take acetaminophen and ibuprofen alternating every 3 hours for pain
4) Limited intraoperative opioid administration	4) Targeted Discharge Opioid Prescription: <ul style="list-style-type: none"> a. Opioid sparing (OS) cohort: (10 pills of 5milligram oxycodone or 50 milligram tramadol) b. Zero Opioid (ZO) cohort: no opioid prescription provided at discharge
5) Local anesthetic (bupivacaine 0.5%) administered at incision site	

348 *Abbreviations: PACU = post-anesthesia care unit*

349 **Table 2.** Demographic and Clinical Characteristics

	Control (n=58)	Opioid Sparing (n=42)	Zero-Opioid (n = 29)	P value
Age (years), Mean \pm SD	52.4 \pm 1.8	55.3 \pm 2.0	58.6 \pm 2.9	0.360
Female Sex, N (%)	19 (32.8)	10 (23.8)	2 (6.9)	0.029*
Race/Ethnicity, N (%)				0.233
<i>Black</i>	3 (5.3)	5 (11.9)	7 (24.1)	
<i>White</i>	47 (81.0)	31 (73.8)	22 (75.9)	
<i>Hispanic, Non-Black</i>	5 (8.6)	4 (9.5)	0 (0)	
<i>Asian</i>	2 (3.4)	1 (2.4)	0 (0)	
<i>Other</i>	1 (1.7)	1 (2.4)	0 (0)	
BMI (kg/m²), Median (IQR)	27.8 (25.4-32.1)	27.9 (24.3-31)	25.4 (23.3-28.7)	0.065
ASA Class, N (%)				0.124
≤ 2	46 (79.3)	28 (66.7)	17 (58.6)	
≥ 3	12 (20.7)	12 (28.6)	12 (41.4)	
Smoking Status, N (%)				0.754
<i>Former</i>	16 (27.6)	14 (33.3)	10 (34.5)	
<i>Current</i>	6 (10.3)	7 (16.7)	4 (13.8)	
History of Substance Abuse, N (%)	3 (5.2)	5 (11.9)	4 (13.8)	0.332

350 *Abbreviations: SD = standard deviation; BMI = body mass index; IQR = interquartile range; ASA*
351 *= American Society of Anesthesiologists*
352 ** denotes statistical significance*

353 **Table 3.** Perioperative Characteristics

	Control (n=58)	Opioid Sparing (n=42)	Zero-Opioid (n=29)	P value
Inguinal Hernia Repair, N (%)	32 (55.2)	31 (73.8)	25 (86.2)	0.009*
Procedure Technique, N (%)				0.017*
Open	10 (17.2)	15 (35.7)	11 (37.9)	
Minimally Invasive (Laparoscopic/Robotic)	48 (82.8)	27 (64.3)	18 (62.1)	
<i>Laparoscopic cholecystectomy, N (%)</i>	26 (54.2)	11 (40.7)	4 (22.2)	
<i>TAPP Inguinal, N (%)</i>	22 (45.8)	11 (40.7)	14 (77.8)	
<i>TEP Inguinal, N (%)</i>	0	5 (18.6)	0	
Length of Procedure (min.), Median (IQR)	101 (80-116)	108 (92-132)	96 (79-126)	0.238
Estimated Blood Loss (mL), Median (IQR)	10 (0-10)	5 (0-20)	0 (0-10)	0.0104*
Total Intravenous Fluid Given (mL), Median (IQR)	1000 (700- 1200)	700 (84- 1000)	1000 (800- 1000)	0.0039*
Total Local Anesthesia Given (mL), Median (IQR)	30 (30-30)	30 (30-30)	30 (30-30)	0.27
Total Intraoperative MME, Median (IQR)	480 (480- 720)	420 (240- 480)	480 (240- 480)	0.0001*
Length of Stay after Procedure (hr), Median (IQR)	2.7 (2.4-3.1)	4.7 (3.8-5.4)	5.1 (4.8-5.7)	0.0001*
Pain Scores 1 hour after Procedure, Median (IQR)	2 (1-5)	3 (1-6)	1 (1-5)	0.061
Pain Scores at Discharge, Median (IQR)	4 (1-6)	2 (1-4)	3 (1-4)	0.062

354 *Abbreviations: TAPP = trans-abdominal pre-peritoneal; TEP = totally extra-peritoneal; min. =*
355 *minutes; IQR = interquartile range; mL = milliliters; MME = morphine milligram equivalents; hr =*
356 *hours*

357 ** denotes statistical significance*

358

359 **Table 4.** Postoperative Outcomes

	Control (n=58)	Opioid Sparing (n=42)	Zero-Opioid (n=29)	<i>P</i> value
Total MME in PACU, Median (IQR)	15 (7.5-22.5)	7.5 (7.5-15)	15 (7.5-15)	0.3368
Total MME after Discharge, Median (IQR)	46 (37.5 – 75)	15 (11 – 22.5)	0 ± 0	0.0001*
Pain Scores after Discharge, Median (IQR)	3 (1-4)	2 (1-3)	4 (3-5)	0.08
Satisfaction Scores after Discharge, Median (IQR)	10 (9-10)	10 (9-10)	10 (8.5-10)	0.8302
Calls to Surgeon's Office with Pain within 30d, N (%)	10 (17.2)	10 (23.8)	0 (0)	0.022*
Pain Medication Refills within 30d, N (%)	3 (5.2)	4 (9.5)	0 (0)	0.218

360 *Abbreviations: MME = morphine milligram equivalents; PACU = post-anesthesia care unit; IQR*
361 *= interquartile range; d = days*
362 ** denotes statistical significance*

363 **FIGURE TITLES and LEGENDS:**

364 **Figure 1.** *Preoperative Opioid Reduction Patient Education Handout for Inguinal Hernia Repair.*
365 An alternative, but similar handout was created for cholecystectomy.

366 **Figure 2.** *Study timeline with assessment and intervention time periods*

367 **Figure S1.** *Postoperative Opioid Use, Pain, and Satisfaction Survey* (intended for internal use
368 only)